Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs Zimmer Biomet Holdings Inc — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.52, while Zimmer Biomet Holdings Inc trades at $96.43 (market cap $18.55B). The key difference: Zimmer Biomet Holdings Inc pays a 0.99% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals.
| SGOV | ZBH | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $100.74 | $107.71 |
52-Week Low | $100.28 | $79.58 |
Market Cap | — | $18.55B |
Enterprise Value | — | $25.61B |
Dividend Yield | — | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV (iShares 0-3 Month Treasury Bond ETF) trades at $100.515 with minimal daily movement (+0.01%). The ETF shows bearish technical signals with moving averages indicating selling pressure, though oscillators are neutral. Recent institutional activity shows mixed positioning with some firms increasing stakes while others reduced exposure. The fund provides exposure to ultra-short-term Treasury bonds with monthly distributions, currently yielding approximately 3.8%.
SGOV serves as a defensive cash alternative amid market volatility, offering principal protection and minimal interest rate risk. The fund benefits from rising benchmark rates but faces pressure from potential Fed rate hikes and inflation concerns. Current macro uncertainty and steepened yield curve create both opportunity and risk for Treasury-focused investors.
ZBH trades at $96.04, down 1.78% today, with a bullish technical signal from moving averages and a consensus analyst price target of $103.56. Recent Q2 2026 earnings beat expectations with EPS of $2.07 versus $2.01 expected, and the company raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23 billion and a net income margin of 8.56%.
The outlook is positive given earnings momentum and raised guidance, but risks include competitive pressures and debt levels, with the debt-to-asset ratio rising to 32.57% in 2025. Analyst sentiment is mixed with 40% buy ratings, offering a potential 7.8% upside to the consensus target, though investors should monitor margin trends and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
